IHI Corporation

IHI Corporation concentrates on healthcare and life sciences, specifically biotechnology, digital health, and medical devices. The firm seeks opportunities where scientific innovation intersects with large addressable markets, with a particular interest in platform technologies that can scale across regulatory jurisdictions. This focus is consistent across all of its office locations.

The firm's offices in London, Singapore, Boston, Tokyo, Seoul, Denver, and San Ramon create a trans-Pacific corridor for deal flow. IHI Corporation uses this footprint to source Asia-based healthcare innovations and prepare them for FDA or EMA regulatory pathways, while also helping Western life-science companies access Asian commercial markets and manufacturing partners. Few firms of comparable scale operate across all three major global innovation hubs simultaneously.

George Chuang, the Chief Executive Officer, leads the firm's investment activities. The firm operates with a principal-led model where senior decision-makers are directly involved in sourcing, diligence, and portfolio management rather than delegating to junior staff. This concentrated decision-making structure is common among specialized healthcare investment firms targeting early-stage and growth-equity opportunities.

IHI Corporation engages across early-stage venture and growth-equity stages within healthcare. The firm typically enters at Series A or B for biotech platform companies and later-stage growth rounds for medical device and digital health companies with existing regulatory clearances. The firm does not publicly disclose a strict stage mandate, but its deal history suggests flexibility based on scientific maturity rather than rigid funding-round labels.

IHI Corporation structures its healthcare investments primarily as direct equity positions. While the firm's public communications emphasize direct deals, it may participate in special-purpose vehicles for specific co-investment opportunities. The firm does not publicly operate as a fund-of-funds, distinguishing it from multi-strategy allocators that blend primary fund commitments with direct co-investments.

IHI Corporation, the healthcare-focused investment firm led by George Chuang, is a separate entity from the Japanese heavy-industry conglomerate IHI Corporation (formerly Ishikawajima-Harima Heavy Industries). The shared name is coincidental; the investment firm is not a subsidiary, spinout, or affiliate of the Japanese industrial group. Allocators should verify legal entity identifiers during due diligence to avoid confusion.

IHI Corporation selectively co-invests alongside other healthcare-specialist funds, particularly for larger growth rounds where syndicate construction benefits portfolio companies. The firm's distributed office model makes it an attractive co-investor for US-based funds seeking Asia-Pacific market insight and for Asian funds seeking FDA regulatory expertise. Co-investment terms are negotiated on a deal-by-deal basis.